Kelly Huang has notified the Board of Directors of Obalon Therapeutics, Inc. of his resignation from his position as President and Chief Executive Officer, effective May 20, 2019. In connection with Mr. Huang's termination of his employment with the Company as of the Effective Date, Mr. Huang is expected to continue to serve as a consultant to the Company. Also effective as of May 20, 2019, William Plovanic has been promoted to President and will retain his title as Chief Financial Officer.

Mr. Plovanic was also appointed to serve as a Class I director on the Board.